{"schema_version":"1.0","type":"article","title":"AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.md","lang":"zh-Hant","date":"2026-06-24","publish_at":"2026-06-24T08:13:00+08:00","updated_at":"2026-06-24","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","臨床數據","生技投資","製藥巨頭"],"summary":"過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…","key_points":[],"facts":[],"sections":["武田製藥闖入一場大考：Zasocitinib 頭對頭打敗 Sotyktu","01｜乾癬治療的標準，已經從 PASI 75 卷到 PASI 100","02｜Zasocitinib 的價值：AI 分子設計，不只是行銷名詞","03｜TYK2 為什麼重要？它是 JAK 風險之後的「窄門」","04｜Sotyktu 的教訓：口服方便，不等於商業成功","05｜生物製劑仍然是高牆：Skyrizi 的存在感太強","06｜Icotyde、Zasocitinib、Envudeucitinib：口服乾癬藥開始進入三國時代","07｜Zasocitinib 的真正大市場，不只在乾癬","08｜台灣可以怎麼看？","結語｜武田已經通過臨床考試，但真正的大考才開始"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-oral-psoriasis-pill-2026-03-18/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-oral-psoriasis-pill-2026-03-18/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"In a head-to-head Phase 3 study, zasocitinib showed statistical superiority over deucravacitinib across key endpoints in plaque psoriasis.","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Design of a highly selective, allosteric, picomolar TYK2 inhibitor using novel FEP+ strategies - Schrödinger","source":"","date":"","url":""},{"title":"https://www.schrodinger.com/design-of-a-highly-selective-allosteric-picomolar-tyk2-inhibitor-using-novel-fep-strategies/","source":"","date":"","url":"https://www.schrodinger.com/design-of-a-highly-selective-allosteric-picomolar-tyk2-inhibitor-using-novel-fep-strategies/"},{"title":"www.schrodinger.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-ai-crafted-psoriasis-pill-succeeds-late-stage-studies-2025-12-18/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-ai-crafted-psoriasis-pill-succeeds-late-stage-studies-2025-12-18/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"Takeda’s Phase 3 studies in plaque psoriasis demonstrate that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 1）","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-01.webp"},{"alt":"Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 2）","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-02.webp"},{"alt":"Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 3）","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-03.png"},{"alt":"Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 4）","url":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/cover.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-24）。AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu。https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-24-ai-zasocitinib-sotyktu-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}